Michael Aberman is a Pioneer at Artis Ventures. He previously served as the SVP of Strategy and Investor Relations at Regeneron Pharmaceuticals, and the CEO of Quentis Therapeutics.
As a Pioneer, Michael brings over a decade of pharma and biotech strategy and startup experience. He currently advises several Artis portfolio companies including Unnatural Products and serves as the Interim CBO at Excision Biotherapeutics.
Michael Aberman, MD
FORMER SVP, STRATEGY AND IR, REGENERON